Skip to content

Efficacy and safety of narrow-band-UVB treatment for plaque psoriasis in Chinese: a prospective, single-center, randomized, single-blind, parallel-controlled study

Efficacy and safety of narrow-band-UVB treatment for plaque psoriasis in Chinese: a prospective, single-center, randomized, single-blind, parallel-controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025618
Enrollment
Unknown
Registered
2019-09-02
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

A:10% dose increment
B:20% dose increment
C:30% dose incremen

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients (aged from 18 to 70 years); 2. Stable ( >=6 months) mild to severe chronic plaque psoriasis; 3. Without phototherapy in the past 6 months; 4. Reduce exposure to the sun; 5. Written informed consent is given.

Exclusion criteria

Exclusion criteria: 1. Other types of psoriasis or other skin diseases that may influence a disease assessment; 2. History of skin cancer or solar keratosis; 3. History of taking photosensitizing drugs or photosensitive skin disease; 4. Pregnant or breastfeeding woman; 5. With severe comorbidities; 6. Systemic treatment for psoriasis in the past 1 months; 7. Topical treatment for psoriasis in the past 2 weeks; 8. Biological treatment for psoriasis in the past 6 months; 9. Other conditions not suitable for the study.

Design outcomes

Primary

MeasureTime frame
psoriasis area and severity index;Physician's Global Assessment;

Countries

China

Contacts

Public ContactDing Yangfeng

Shanghai Skin Disease Hospital

dingyangfeng@hotmail.com+86 15021155088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026